2.83
Immix Biopharma Inc Aktie (IMMX) Neueste Nachrichten
What analysts say about Immix Biopharma Inc. stockFree Stock Market Knowledge Sharing - Autocar Professional
Is Immix Biopharma Inc. a good long term investmentRecord-setting profit potential - jammulinksnews.com
Immix Biopharma Inc. Stock Analysis and ForecastUnrivaled growth potential - jammulinksnews.com
What drives Immix Biopharma Inc. stock priceTremendous wealth creation - jammulinksnews.com
What makes Immix Biopharma Inc. stock price move sharplyFree AI-Powered Stock Predictions - Newser
Why Immix Biopharma Inc. stock attracts strong analyst attentionHigh Yield Opportunities - Newser
How Immix Biopharma Inc. stock performs during market volatilityBreakout Level Watch - Newser
ImmixBio reports no neurotoxicity in CAR-T therapy for AL amyloidosis - Investing.com Nigeria
ImmixBio reports no neurotoxicity in CAR-T therapy for AL amyloidosis By Investing.com - Investing.com South Africa
Immix Biopharma Says NXC-201 Safety Profile Shows Absence of Neurotoxicity in Low-Volume Disease - MarketScreener
Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion - MarketScreener
Immix Biopharma Reports Class-Leading Safety Profile for CAR-T NXC-201 in Low-Volume AL Amyloidosis, On Track for BLA Submission - Nasdaq
Revolutionary CAR-T Safety Data: IMMX Reports Zero Neurotoxicity in Rare Disease Treatment - Stock Titan
Immix Biopharma (NASDAQ:IMMX) Stock Price Up 1.5% – Here’s Why - Defense World
Immix Biopharma stock advances as H.C. Wainwright reiterates Buy rating By Investing.com - Investing.com Nigeria
Immix Biopharma stock advances as H.C. Wainwright reiterates Buy rating - Investing.com
Immix Biopharma Expands NEXICART-2 Trial Sites Nationwide, Progressing Towards Biologics License Application for Cell Therapy in AL Amyloidosis - Nasdaq
Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis - GlobeNewswire
Breakthrough Cell Therapy for AL Amyloidosis Accelerates Toward FDA Approval with 18 Trial Sites - Stock Titan
Immix Biopharma (NASDAQ:IMMX) Upgraded by Wall Street Zen to Hold Rating - Defense World
Immix Biopharma Holds Annual Meeting, Elects Directors - TipRanks
Immix Biopharma CEO Rachman buys $4998 in shares - Investing.com
Jane Street Group LLC Invests $39,000 in Immix Biopharma, Inc. (NASDAQ:IMMX) - Defense World
H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial - MSN
Immix Biopharma (IMMX) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Q3 EPS Estimates for Immix Biopharma Raised by HC Wainwright - Defense World
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):